Table 3. Incremental cost-effectiveness ratios of including pre-adolescent boys in the childhood vaccination program compared to vaccination of pre-adolescent girls only.
| Vaccination strategya | ||
| HPV-related outcome(s) included | Girls onlyb | Girls + boysc |
| Cervix only | $20,600 | $145,500 |
| Female cancersd | $12,800 | $119,300 |
| Female + male cancerse | $8,900 | $81,700 |
| All HPV-related conditionsf | $5,000 | $60,100 |
a
Assumes a cost per dose of $75, exclusive of the administration cost (≈$14 per dose).
b
Compared to no vaccination.
c
Compared to girls-only vaccination.
d
Includes female cervical, vulvar, vaginal, anal and oropharyngeal cancers,
e
Includes male anal, oropharyngeal and penile cancers,
f
Includes cervical, vulvar, vaginal, anal, oropharyngeal and penile cancers related to HPV-16, -18, and genital warts and recurrent respiratory papillomatosis related to HPV-6, -11.